Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes. 2014

Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
Institute of Molecular Pharmacology, Research Centre for Natural Sciences, HAS, 1117 Budapest, Magyar Tudósok körútja 2, Hungary.

Several studies have reported that statins occasionally cause impairment of liver functions characterized by elevated serum bilirubin levels, which might be due to altered function of the multidrug resistance-associated proteins (Mrp2/3). We aimed to study the modulation of the hepatobiliary transport of bilirubin by four statin derivatives, atorvastatin, fluvastatin, pravastatin, and rosuvastatin in sandwich-cultured rat hepatocytes. All statins except pravastatin significantly inhibited the uptake of bilirubin. The biliary efflux of bilirubin conjugates was increased by pravastatin and rosuvastatin concentration dependently. Rosuvastatin stimulated not only the Mrp2 mediated biliary, but the Mrp3 mediated sinusoidal elimination, resulting in decreased intracellular bilirubin accumulation. The significantly induced Mrp2/3 protein levels (ranging from 1.5 to 1.8-fold) accounted for the elevated efflux. Cell polarization, the formation of biliary network was also significantly increased by fluvastatin, pravastatin and rosuvastatin (151%, 216% and 275% of the control, respectively). The simultaneous inhibition of the uptake and the stimulation of the sinusoidal and canalicular elimination may explain, at least in part, the clinical observation of elevated serum bilirubin levels. In conclusion, our results suggest that in spite of the elevated serum bilirubin levels, the altered Mrp2 and Mrp3 functions by statins is probably not associated with hepatotoxic effects.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005229 Fatty Acids, Monounsaturated Fatty acids which are unsaturated in only one position. Monounsaturated Fatty Acid,Acid, Monounsaturated Fatty,Acids, Monounsaturated Fatty,Fatty Acid, Monounsaturated,Monounsaturated Fatty Acids
D005464 Fluorobenzenes Derivatives of BENZENE that contain FLUORINE. Fluorobenzene
D006538 Heptanoic Acids 7-carbon saturated monocarboxylic acids. Acids, Heptanoic
D000068718 Rosuvastatin Calcium A HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for CARDIOVASCULAR DISEASES. Crestor,Rosuvastatin,ZD 4522,ZD4522,Calcium, Rosuvastatin
D000069059 Atorvastatin A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors. (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid,Atorvastatin Calcium,Atorvastatin Calcium Anhydrous,Atorvastatin Calcium Hydrate,Atorvastatin Calcium Trihydrate,Atorvastatin, Calcium Salt,CI 981,CI-981,Lipitor,Liptonorm,CI981
D000077340 Fluvastatin An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4. 7-(3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate,Fluindostatin,Fluvastatin Sodium,Fluvastatin Sodium Salt,Lescol,XU 62-320,XU 62320,XU-62320,XU 62 320,XU62320

Related Publications

Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
June 2015, Toxicological sciences : an official journal of the Society of Toxicology,
Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
March 2005, Drug metabolism and disposition: the biological fate of chemicals,
Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
August 2020, The AAPS journal,
Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
January 2014, Toxicology letters,
Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
January 2009, Molecular pharmaceutics,
Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
January 1979, The American journal of physiology,
Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
September 2008, American journal of physiology. Gastrointestinal and liver physiology,
Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
October 2013, Drug metabolism and disposition: the biological fate of chemicals,
Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
June 2010, Molecular pharmaceutics,
Mónika Szabó, and Zsuzsa Veres, and Attila Bátai-Konczos, and Orsolya Kékesi, and Emese Kis, and Kitti Szabó, and Katalin Jemnitz
June 2001, In vitro cellular & developmental biology. Animal,
Copied contents to your clipboard!